Astrana targets $72.5M-$77.5M Q3 adjusted EBITDA while raising 2026 adjusted EBITDA to $255M-$280M (NASDAQ:ASTH)
· seekingalpha.com
Astrana Health (ASTH) Q2 2026 earnings call recap: raised adjusted EBITDA guidance, strong cash flow, MA growth, Medi-Cal shifts & deleveraging—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...